if u listen to conference call plc mention something like they expect renal guard sales to double in 2010 from previouse year and that does not equal very much revs only about $300k in total..........as much of a lager plc tmr has been it needs to perform alot better but i still think plc shares will be extremely diluted as it stands now imo. to buy or buy more as a lottery ticket i would think under .03
Dilution implies a buyer for stock or convertible securities. i think PLC is too sick for that. Too many shares are completely illiquid for a cheapie tender offer--ask prices often over $1 show that.
If RG becomes the standard of care in Italy, sales go up a lot more than 2x (that's imaginable next year, not this). That probably would be enough to generate a clinical trial in Northern Europe somewhere, with the promise of a survivable business. I think everyone is sick enough of this company so any realistic offer for all of it would go through. (Even if they aren't defensible, the RG patents would be worth $25MM for nuisance value, should the procedure take off. If defensible, thay'd be worth at least 10x that).
I don't believe that prior "preventions" for CIN had more than 2 independent positive trials before taking off, so a degree of acceptance is within reach. What I've seen of cost estimates for RG treatment are in the same range as the treatments it is looking more effective than. Adding a nurse to do essentially what a RG console does is more costly, but gives labs a chance to see a proof-of-principle in the flesh.